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Abstract
Background: Studies in women with post-menopausal osteoporosis have shown that discon-
tinuation of treatment with denosumab leads to an increased risk of vertebral fractures be-
cause of rebound bone turnover and rapid loss of bone mineral density (BMD). Methods: In 
a post hoc analysis of the Prolia for Osteoporosis of Transplant Operated Patient study, we 
analyzed the effect of denosumab withdrawal on BMD changes. Twenty-five de novo kidney 
transplant recipients (KTR) who were treated for 1 year with 2 six-monthly doses of deno-
sumab on top of standard treatment (daily calcium and vitamin D) were compared to a control 
group of 29 KTR who received standard treatment alone. BMD changes were analyzed by re-
peated dual-energy X-ray absorptiometry shortly after transplantation (baseline), after 6 and 
12 months (active treatment phase) and after 2–6.5 years (follow-up phase). Results: The av-
erage BMD at the lumbar spine declined markedly after discontinuation of treatment with 
denosumab but increased again thereafter. Thus, the average monthly change in lumbar spine 
BMD from month 12 onward was only 0.1 ± 2.8‰ in the denosumab group but 1.5 ± 1.9‰ 
in the control group (p = 0.021). The average monthly change in lumbar spine BMD from base-
line to follow-up was similar in the control and denosumab group (1.1 ± 1.2‰ vs. 1.5 ± 2.4‰, 
p = 0.788). Similar results were seen at the total hip. Conclusions: In de novo KTR treated with 
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2 doses of denosumab, we detect a marked decrease in lumbar spine and hip BMD when de-
nosumab is discontinued. Denosumab treatment should therefore not be discontinued with-
out considering an alternative antiresorptive treatment. © 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
Loss of bone mineral density (BMD) is common in kidney transplant recipients (KTR), in 
particular in the first year after transplantation, due to the effects of immunosuppressive 
medication (especially glucocorticoids), persistence of elevated PTH and FGF-23 levels, and 
low vitamin D status [1]. Hence, there is also a heightened risk for developing or worsening 
osteoporosis and bone fractures [2, 3]. Supplementation with calcium and vitamin D and its 
analogues as well as treatment with bisphosphonates are therapeutic options to improve the 
loss of bone mass after renal transplantation.
Denosumab is a fully human monoclonal antibody with high affinity and specificity for Receptor Activator of Nuclear Factor κB ligand (RANKL), which inhibits osteoclast formation, 
function and survival. Denosumab thereby reduces bone resorption and improves BMD, and 
is therefore used for treatment of osteoporosis and prevention of fractures [4–7]. The pivotal 
randomized, double-blind, placebo-controlled, phase 3 Fracture Reduction Evaluation of Deno-
sumab in Osteoporosis Every 6 Months trial in women with postmenopausal osteoporosis 
showed that treatment with denosumab led to a markedly reduced incidence in new vertebral 
fractures, nonvertebral fractures and hip fractures when compared to placebo [8]. In KTR, we 
have recently shown that denosumab (60 mg subcutaneously, given 2 weeks after surgery and 
after 6 months) effectively increased BMD in the first year after kidney transplantation [9].
Several studies in women with post-menopausal osteoporosis, including a post hoc analysis 
of the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months trial and its 
extensions [10–12], have shown that discontinuation of treatment with denosumab leads to an 
increased risk of vertebral fractures due to enhanced bone turnover and rapid loss of BMD. 
After 7 or 10 years of treatment with denosumab, the discontinuation of the treatment resulted 
in a rapid decrease in BMD over 1 year [10]. Miller et al. [7] showed that the inhibitory effects 
of denosumab on bone turnover were reversed after discontinuation of denosumab but restored 
with subsequent retreatment. These findings are in line with several case reports of patients 
who developed multiple new vertebral fractures after discontinuation of denosumab [13–17] 
as well as a significant bone loss [18] after the withdrawal of denosumab.
The aim of the present study was to extend these findings to the setting of renal trans-
plantation. Thus, we analyzed the follow-up changes in BMD in KTR who received 60 mg 
denosumab shortly after and 6 months after transplantation to examine whether there is a 
significant loss in BMD upon denosumab withdrawal in these patients.
Materials and Methods
Details of the Prolia for Osteoporosis of Transplant Operated Patients (POSTOP) study 
have been reported previously [9]. In brief, we recruited a total of 90 KTR that had been trans-
planted less than 4 weeks ago (mean 16 days) to examine 0.5 and 1-year changes in BMD at 
the lumbar spine and the hip by dual-energy X-ray absorptiometry (DXA). The patients were 
randomly assigned (1: 1) to open-label treatment with denosumab 60 mg subcutaneously at 
baseline and after 6 months (n = 46) or no treatment (n = 44). Treatment with denosumab 
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was terminated after 1 year. All patients were prescribed daily calcium (1,000 mg) and 
vitamin D (800 IU). All participants gave their written informed consent. The study was 
designed and conducted to conform to the principles of the Declaration of Helsinki, was 
approved by the local Ethics Committee (IRB approval number 2011–0032), and was regis-
tered on ClinicalTrials.gov, number NCT01377467.
In the present retrospective analysis of the POSTOP study, we analyzed the course of 
BMD in a subset of patients that had at least one follow-up DXA. Thus, 25 de novo KTR with 
denosumab withdrawal could be compared to 29 control KTR who had not received deno-
sumab. After the initial 1-year study period, patients were seen at our transplant center or by 
their local nephrologists for regular clinical and laboratory transplant follow-up. The decision 
to perform additional DXA was made by the treating nephrologist and took place between 3 
and 7.5 years after baseline.
To quantify the changes of BMD over time we calculated the average monthly change in 
lumbar spine and hip BMD for 4 different time intervals: (1) from baseline to 6 months after 
baseline to calculate the early response to denosumab; (2) from baseline to 12 months after 
baseline to calculate the full response to ongoing denosumab treatment; (3) from 12 months 
onward to follow-up visit to estimate the withdrawal effect and (4) from baseline to follow-
up visit to quantify the overall effect of a 1-year “prophylactic” denosumab treatment regime 
(Fig. 1).
Statistics
Baseline characteristics were compared between the treatment groups with a Wilcoxon 
rank sum test for continuous data, and a chi-square or Fisher’s exact test for categorical data. 
The percentage change of BMD at the lumbar spine and the hip was divided by months after 
baseline visit or after 12 month’s visit, and was compared between the treatment groups with 
a Wilcoxon rank sum test. All analyses were performed in the R programming language (version 
3.3.3) [19]. The package “ggplot2” [20] was used to plot the figures and fit the total lumbar and 
hip BMD by time, using local fitting (loess) with a span (degree of smoothing) of 0.85.
Results
From the initial 90 KTR in the POSTOP study we were able to obtain follow-up DXA 
measurements in 54 patients. A total of 45 KTR had one, and 9 patients had 2 additional DXAs 
in the follow-up phase; 25 patients had been treated with denosumab for 1 year and 29 
patients had not received denosumab.
Fig. 1. Scheme depicting the time 
intervals for calculation of month-
ly change in BMD.
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The baseline patient characteristics of the 54 KTR are shown in Table 1. The study popu-
lation had a mean age of 51 ± 13 years; 57.4% were male and all were of white ethnicity; mean 
baseline eGFR was 55.4 ± 16.0 mL/min/1.73 m2. All patients were initially treated with triple 
immunosuppression, including a calcineurin antagonist, mycophenolate mofetil and gluco-
corticosteroids. Of all patients, 24 (44%) had osteopenia and another 9 (17%) had osteopo-
rosis. The baseline characteristics of the subset of the POSTOP study patients (n = 54) did not 
differ from the original study population (n = 90; data not shown).
The 2 study groups were generally well balanced except that more patients in the control 
group were osteopenic (57%) or osteoporotic (21%) than in the denosumab group (32 and 
12%, respectively). Also, there were less men (n = 13, 45%) in the control group than in the 
denosumab group (n = 18, 72%) and there were less living donor transplantations in the 
control group (38%) than in the denosumab group (64%). A total of 22 patients (76%) in the 
control group were on hemodialysis and 1 (3%) was a pre-emptive transplantation, while 13 
(52%) in the denosumab group were on hemodialysis and 8 (32%) had a pre-emptive trans-
plantation. The biochemical parameters of bone metabolism at baseline were balanced 
between the 2 treatment groups. In particular, patients had similar levels of PTH and 
25-hydroxyvitamin D.
Figure 2 depicts the change of total lumbar BMD over time by the randomization group. 
Locally weighted regression (loess) analysis revealed that the previously increased BMD at 
the lumbar spine (baseline to 12 months) declined markedly after discontinuation of the 
treatment with denosumab, suggesting that the treatment effect was lost within 6–12 months. 
The BMD increased again thereafter, but at a lower rate.
Figure 3 depicts the change of total hip BMD over time by randomization group. A similar 
decrease of BMD was seen after discontinuation of denosumab treatment, with a slower 
increase of BMD thereafter. This demonstrates that the rapid decrease of BMD after deno-
sumab withdrawal is occurring at different skeletal sites.
In Figure 4, it is shown that denosumab very effectively increased BMD at the lumbar 
spine and total hip in the first 6 and 12 months. When averaging BMD from baseline to the 
Table 1. Demographic and baseline characteristics of transplanted patients
Characteristics Control group (n = 29) Denosumab group (n = 25)
Age, years 49.8±13.1 51.4±13.0
Gender, male, n (%) 13 (45) 18 (72)
BMI, kg/m2 24.7±4.5 25.7±4.7










Deceased donor transplantation, n (%) 18 (62) 9 (36)
Repeat transplantation, n (%) 5 (17) 4 (16)
eGFR, mL/min/1.73 m2 56.1±16.7 54.5±15.6
PTH, ng/L 126.7±87.4 182.1±196.125-hydroxyvitamin D, μg/L 19.0±9.2 16.4±9.2
Total lumbar spine BMD, g/cm2 0.917±0.135 0.994±0.138
Total hip BMD, g/cm2 0.843±0.093 0.903±0.131
Osteopenic, n (%) 16 (57) 8 (32)
Osteoporotic, n (%) 6 (21) 3 (12)
Values show means ± SD if not otherwise stated.
eGFR, estimated glomerular filtration rate; BMD, bone mineral density; BMI, body mass index.
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Fig. 2. Change of total lumbar 
BMD (g/cm2) over time by the 
randomization group. Thin lines 
show the course of total lumbar 
BMD of individual patients of the 
original POSTOP group (n = 88); 
the thick black line shows the av-
erage trend by using locally 
weighted regression analysis 
(loess); the dashed line indicates 
12 months after baseline visit 
(end of denosumab effect). BMD, 
bone mineral density.
Fig. 3. Change of total hip BMD 
(g/cm2) over time by the random-
ization group. Thin lines show 
course of total hip BMD of individ-
ual patients of the original POST-
OP group (n = 88); the thick black 
line shows the average trend by 
using locally weighted regression 
analysis (loess); the dashed line 
indicates 12 months after base-
line visit (end of denosumab ef-
fect). BMD, bone mineral density.
Fig. 4. Monthly changes in ‰ 
from baseline to 6 months (Com-
parison 1); from baseline to 12 
months (Comparison 2); from 
month 12 to follow-up visit (Com-
parison 3); and from baseline to 
follow-up visit (Comparison 4). 
Bar graphs show the mean and 
SEM. BMD, bone mineral density.
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follow-up visit (median 41.8 months, IQR 13.6 months), the change of total lumbar BMD was 
not significantly different in the control and denosumab groups (1.1 ± 1.2‰ vs. 1.5 ± 2.4‰, 
p = 0.788). Likewise, the total hip BMD average monthly change was similar in both groups 
(0.5 ± 1.3‰ vs. 0.9 ± 2.0‰, p = 0.869). Of importance, the average monthly change in lumbar 
spine BMD from month 12 onward was 1.5 ± 1.9‰ in the control group, but substantially less 
at 0.1 ± 2.8‰ in the denosumab group (p = 0.021). Likewise, the average monthly change in 
hip BMD tended to be higher in the control than that in the denosumab group, albeit not 
significantly (0.6 ± 1.7‰ vs. 0.2 ± 2.3‰, p = 0.294).
To consolidate these data, we performed a subanalysis by dividing the study patients in 
both groups according to 3 different lumbar spine BMD change categories (from month 12 to 
follow-up) as follows: (1) patients with >+2.5‰ per month BMD change (gain group); (2) 
patients with –2.5 to +2.5‰ per month BMD change (stable group); and 3) patients with less 
than –2.5‰ per month BMD change (loss group). As can be seen in Table 2, denosumab 
treatment compared with control resulted in more patients in the loss group (12 vs. 0%) and 
fewer in the gain group (16 vs. 28%), confirming our main data.
We were also interested to determine whether the use of steroids was similar in both 
treatment groups. Previously we reported that during the 12-month treatment phase the 
cumulative amount of steroids was similar (3.760 vs. 3.974 g in control vs. denosumab group). 
We calculated the cumulative amount of steroids from 12 months until follow-up and did 
not find a significant difference (control group 0.727 ± 1.722 g, denosumab group 1.575 ± 
2.779 g, p = 0.293).
Discussion
Densoumab is a first-in-class anti-osteoporotic drug, which is highly effective in preventing 
vertebral and non-vertebral fractures in postmenopausal women with osteoporosis [8]. 
When compared with bisphosphonates in this patient population, it has superior efficacy on 
BMD at all measured skeletal sites [21], although a recently published meta-analysis could 
not show a significantly reduced fracture risk under denosumab compared to bisphospho-
nates despite higher gains in BMD; thus, there has not been a documented superiority on 
fracture risk reduction so far [22, 23]. Recently, several studies in women with post-meno-
pausal osteoporosis [10, 12, 24] have shown that discontinuation of treatment with deno-
sumab leads to enhanced bone turnover and rapid loss of BMD within a relatively short time 
with a substantially increased incidence of vertebral fractures.
In this post hoc analysis of the POSTOP study, we also detected a drop in lumbar and hip 
BMD in de novo KTR when denosumab is discontinued, most likely because of upregulation 
of osteoclastogenesis and osteoclast activity [25]. Thus, the gain in BMD in the 12 months of 
treatment was lost upon discontinuation of denosumab. Fortunately however, at an average 
follow-up of 42 months the BMD was not inferior to the control group. We did not see a signif-
Control (n = 29) Denosumab (n = 25)
Gain group 8 (28) 5 (16)
Loss group 0 (0) 3 (12)
Stable group 21 (72) 18 (72)
Number of patients and % of all patients in each group are indicated.
BMD, bone mineral density.
Table 2. Subanalysis of monthly 
lumbar spine BMD change (in 
‰) 12 months until follow-up
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icant difference in the cumulative amount of steroids that the patients received in the 2 
treatment groups, excluding that steroids might have affected the results. As there were less 
number of women and less recipients of a deceased donor kidney transplant in the deno-
sumab group, we may have underestimated the magnitude of the denosumab withdrawal 
effect.
It has been suggested that treatment with bisphosphonates might antagonize the 
enhanced bone turnover after withdrawal of denosumab due to their high affinity for bone 
hydroxyapatite and long half-life within the skeleton, persisting for months or even years 
[26]. Indeed, several small studies in postmenopausal women showed that switching to 
bisphosphonates, after having been treated with denosumab, was associated with lower or 
only slightly elevated bone turnover biomarkers such as C-telopeptides or N-telopeptide, a 
stabilized BMD after having gained BMD under denosumab and thus less bone loss [27–29].
Currently, it is therefore advised to administer bisphosphonates after discontinuation of 
denosumab to prevent rapid bone loss in postmenopausal women. Bisphosphonates can be 
given orally like alendronate, which has been shown to maintain BMD after stopping deno-
sumab [30] or intravenously like zoledronate or risedronate [31]. Very recently it was shown 
that de novo KTR with a high fracture risk, who received zoledronic acid in the first year after 
kidney transplantation, had a significant positive effect of zoledronate with an increase of 
BMD in both lumbar spine and total hip sites without the risk of inducing adynamic bone 
disease [32]. Due to the marked but reversible inhibition of bone remodeling under deno-
sumab therapy and due to the higher possibility of impaired renal function in the first year 
after transplantation, starting therapy with denosumab in de novo KTR followed by bisphos-
phonate treatment might therefore be an excellent choice to prevent the loss of BMD after 
kidney transplantation.
Admittedly, our study has several limitations. The sample size was relatively small and 
there were sizable baseline differences between the groups, which could influence BMD. In 
addition loss to follow-up presents a possible selections bias due to considering patients with 
follow-up DXA scans as higher risk patients by their local nephrologists. Furthermore, the 
follow-up DXA measurements were not performed in a systematic fashion at defined time 
intervals, and this resulted in different follow-up periods, thus this analysis is limited in deter-
mining the rate of bone loss following the withdrawal of denosumab. To minimize this limi-
tation, we extended the loess analysis by expressing BMD changes on a monthly basis at 
defined time intervals, and this confirmed the initial findings.
Another important limitation of our study resides in the fact that many KTR had only 
osteopenia or relatively normal BMD. We had initially expected that many more patients 
would develop osteoporosis within 1 year after transplantation, but this was not the case, 
possibly because of ample calcium and vitamin D substitution. Continuing denosumab beyond 
1 year would not make sense in these patients with preserved BMD. Based on our data we 
would recommend that only those KTR with osteoporosis be treated with denosumab, and 
that in these patients continuous treatment would be required beyond 1 year to avoid a rapid 
decline in BMD after the cessation of treatment.
In conclusion, de novo KTR treated with 2 doses of denosumab in the first year show a 
marked decrease in lumbar spine and hip BMD when denosumab is discontinued. Due to the 
retrospective study design, these findings are suggestive and consistent with the literature, 
but further studies need to be performed. Whether subsequent bisphosphonate treatment 
might be effective to prevent the probable decline in BMD after denosumab discontinuation 
would need to be tested in a prospective clinical study.
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